Adgyl Lifesciences Profile
Key Indicators
- Authorised Capital ₹ 16.00 Cr
as on 15-11-2024
- Paid Up Capital ₹ 13.21 Cr
as on 15-11-2024
- Company Age 6 Year, 23 Days
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 8.70 M
as on 15-11-2024
- Revenue 63.30%
(FY 2023)
- Profit 41.38%
(FY 2023)
- Ebitda 54.87%
(FY 2023)
- Net Worth 9.52%
(FY 2023)
- Total Assets 23.42%
(FY 2023)
About Adgyl Lifesciences
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 16.00 Cr and a paid-up capital of Rs 13.21 Cr.
The company currently has active open charges totaling ₹8.70 M.
The Key Managerial Personnel (KMP) at Adgyl Lifesciences Private Limited India is Meenakshi Chakraborty as COMPANY SECRETARY. Neeraj Garg, Rajiv Malik, and Haladasappa Krishnappa serve as directors at the Company.
- CIN/LLPIN
U74999KA2018FTC118861
- Company No.
118861
- Company Classification
Private Limited Foreign Company Incorporated In India
- Incorporation Date
27 Nov 2018
- Date of AGM
29 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Company Details
- Location
Bangaluru, Karnataka, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Adgyl Lifesciences?
Executive Team (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Haladasappa Krishnappa  | Managing Director | 11-Jul-2023 | Current |
| Meenakshi Chakraborty | Company Secretary | 12-Jan-2024 | Current |
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Neeraj Garg | Director | 05-Mar-2019 | Current |
| Rajiv Malik | Director | 27-Nov-2018 | Current |
Financial Performance and Corporate Structure Insights of Adgyl Lifesciences.
Adgyl Lifesciences Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 63.3% increase. The company also saw a substantial improvement in profitability, with a 41.38% increase in profit. The company's net worth moved up by a moderate rise of 9.52%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Adgyl Lifesciences?
In 2023, Adgyl Lifesciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Eurofins Advinus Biopharma Services India Private LimitedActive 6 years 1 monthNeeraj Garg and Rajiv Malik are mutual person
- Eurofins Advinus Discovery Services Private LimitedActive 5 years 9 months
Neeraj Garg and Rajiv Malik are mutual person
- Eurofins Peenya Resources Private LimitedActive 19 years 7 months
Neeraj Garg and Rajiv Malik are mutual person
Eurofins Clinical Diagnostics Bangalore Private LimitedActive 9 years 9 daysNeeraj Garg is a mutual person
Eurofins Amar Immunodiagnostics Private LimitedActive 23 years 2 monthsNeeraj Garg is a mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Axis Bank Limited Creation Date: 27 Mar 2024 | ₹5.67 M | Open |
Axis Bank Limited Creation Date: 31 Oct 2023 | ₹3.03 M | Open |
How Many Employees Work at Adgyl Lifesciences?
Adgyl Lifesciences has a workforce of 241 employees as of Mar 31, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Adgyl Lifesciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Adgyl Lifesciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
